Nuvation Bio
NUVB
Nuvation Bio (NUVB) earnings history
Most recent quarter
- Fiscal period
- Q2 2026
- Period end
- Jun 30, 2026
- EPS actual
- −$0.18
- EPS estimate
- −$0.14
- EPS surprise
- −27.03%
- Revenue surprise
- +17.24%
- Revenue
- $31.7M
- Revenue estimate
- $27.0M
- Reported
- Aug 6, 2026
Earnings history
| Period | Reported | EPS estimate | EPS actual | Surprise | Revenue | Filing |
|---|---|---|---|---|---|---|
| Q2 2026 | Aug 6, 2026 | −$0.14 | −$0.18 | −27.03% | $31.7M | SEC |
| Q1 2026 | May 4, 2026 | −$0.03 | $0.01 | +135.71% | $83.2M | SEC |
| Q4 2025 | Mar 2, 2026 | −$0.09 | −$0.11 | −23.60% | $41.9M | SEC |
| Q3 2025 | Nov 3, 2025 | −$0.17 | −$0.16 | +5.16% | $13.1M | SEC |
| Q2 2025 | Aug 7, 2025 | −$0.17 | −$0.17 | +0.00% | $4.8M | SEC |
| Q1 2025 | May 7, 2025 | −$0.15 | −$0.16 | −6.67% | $3.1M | SEC |
| Q4 2024 | Mar 6, 2025 | −$0.13 | −$0.15 | −16.91% | $5.7M | SEC |
| Q3 2024 | Nov 6, 2024 | −$0.13 | −$0.15 | −19.05% | $727,000.00 | SEC |
| Q2 2024 | Aug 5, 2024 | −$0.06 | −$1.89 | −3130.77% | $1.4M | SEC |
| Q1 2024 | May 14, 2024 | −$0.09 | −$0.07 | +23.66% | $0.00 | SEC |
| Q4 2023 | Feb 29, 2024 | −$0.10 | −$0.06 | +39.58% | $0.00 | SEC |
| Q3 2023 | Nov 2, 2023 | −$0.11 | −$0.09 | +14.29% | $0.00 | SEC |
| Q2 2023 | Aug 3, 2023 | −$0.11 | −$0.09 | +19.86% | $0.00 | SEC |
| Q1 2023 | May 4, 2023 | −$0.10 | −$0.10 | +0.10% | $0.00 | SEC |
| Q4 2022 | Mar 15, 2023 | −$0.12 | −$0.10 | +15.68% | $0.00 | SEC |
| Q3 2022 | Nov 3, 2022 | −$0.14 | −$0.12 | +14.29% | $0.00 | SEC |
| Q2 2022 | Aug 4, 2022 | −$0.13 | −$0.16 | −20.39% | $0.00 | SEC |
| Q1 2022 | May 9, 2022 | −$0.14 | −$0.10 | +28.01% | $0.00 | SEC |
| Q4 2021 | Feb 28, 2022 | −$0.12 | −$0.12 | −3.72% | $0.00 | SEC |
| Q3 2021 | Nov 10, 2021 | −$0.11 | −$0.11 | −4.46% | $0.00 | SEC |
Quarterly revenue
Frequently asked questions
When did Nuvation Bio (NUVB) last report earnings?
Nuvation Bio last reported on Aug 6, 2026, covering fiscal Q2 2026.
Did NUVB beat earnings estimates?
No. Nuvation Bio reported EPS of −$0.18 for Q2 2026 against a −$0.14 estimate — a 27.03% miss.
How much revenue did NUVB report last quarter?
Nuvation Bio reported $31.7M in revenue for Q2 2026, against a consensus estimate of $27.0M.
Earnings figures may be restated, revised or corrected by the issuer. Past results do not indicate future performance.
This page is for informational purposes only. Nothing on it is a recommendation, solicitation or offer to buy or sell any security, nor investment, legal or tax advice. Light Horse Securities Inc does not verify third-party data and is not responsible for its accuracy, completeness or timeliness.